AstraZeneca’s suit accusing Mylan Pharmaceuticals of infringing its patents for an inhaler product is moving to the U.S. District Court for the Northern District of West Virginia, under an Oct. 18 opinion.
Judge Colm F. Connolly, of the U.S. District Court for the District of Delaware, also dismissed Mylan’s motion to dismiss the case for improper venue, given the case will now be tried in the company’s home state. AstraZeneca had opposed the change of venue.
AstraZeneca holds patents for the Symbicort Inhalation Aerosol product, which is a prescription drug used to treat asthma and chronic obstructive pulmonary disease.
Another ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.